Daily, Wed 11 Nov: Frontage take-private, Bayer's asundexian, BeOne's pancreatic cancer pill
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
Basil Lui (linkedin.com/in/basillui) and Ning discuss Charles River, Tigermed and Frontage's chairman taking Hong Kong-listed Frontage private and selling its Pennsylvania testing labs to Charles River; a US-approved RAS inhibitor, daraxonrasib, that Chinese trade reports say is proposed for priority review in China; and Hengrui's oral Lp(a) pill, whose rights outside Greater China sit with Merck. Bayer's asundexian, a factor XIa blood thinner, was approved in China first and then by the FDA. Mirum reports a second Phase 3 win in hepatitis delta, and Beam says its base-edited sickle-cell therapy met its pivotal mark. Beyond biotech: Oura agrees to buy Counsel Health, and Japan's BionicM raises the first close of a Series B for a motorised prosthetic knee.
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice.
Chapters
0:00 Intro and AI-voice disclosure
1:01 Frontage's take-private and the US labs
3:01 BeOne's RAS pill, proposed for priority review
4:27 Hengrui's oral Lp(a) pill, and Merck
5:19 XtalPi, Pierre Fabre, and Shengnuo
6:26 Bayer's asundexian, approved in China first
7:51 Hepatitis delta, and a base-edited sickle-cell therapy
9:29 Beyond biotech: Oura, Counsel Health, and BionicM
10:24 What to watch and sign-off
Key sources: Charles River (company press release) · FDA: daraxonrasib (Rasonque) · FDA: Sunharbo (asundexian) · Mirum: AZURE-4 (company press release) · Beam: BEACON (company press release) · Oura: Counsel Health acquisition
Weekly LinkedIn newsletter
Also listen on: Apple Podcasts · Amazon Music · YouTube